SuperworthLifecore Biomedical EPS LFCR
Diluted earnings per share by quarter and over the last twelve months, from 2010.
- Last 12 months, to Jun 30, 2026
- n/m
- a quarter missing
- Latest quarter, Q2 FY26
- −$0.19
- Fiscal year 2025
- −$1.26
- −648% on the year before
Lifecore Biomedical's twelve-month earnings per share can't be added up yet: a quarter of its results is missing from our data.
In its latest quarter, Q2 FY26, it was −$0.19.
Earnings per share over time
Fiscal year by fiscal year
| Fiscal year | EPS | Change |
|---|---|---|
| FY2025 | −$1.26 | −648% |
| FY2024 | $0.23 | n/a |
| FY2023 | −$3.30 | n/a |
| FY2022 | −$3.96 | n/a |
| FY2021 | −$1.12 | n/a |
| FY2020 | −$1.30 | −6600% |
| FY2019 | $0.02 | −98% |
| FY2018 | $0.89 | +128% |
| FY2017 | $0.39 | n/a |
| FY2016 | −$0.43 | −186% |
| FY2015 | $0.50 | −31% |
| FY2014 | $0.72 | −16% |
| FY2013 | $0.86 | +76% |
| FY2012 | $0.49 | +206% |
| FY2011 | $0.16 | n/a |
Each fiscal year is the twelve months to its fourth quarter.
Quarter by quarter
| Quarter | Ended | EPS | On a year earlier | Last 12 months |
|---|---|---|---|---|
| Q2 FY26 | −$0.19 | n/a | n/a | |
| Q1 FY26 | −$0.43 | n/a | n/a | |
| Q2 FY25 | −$0.29 | −174% | n/a | |
| Q4 FY25 | −$0.06 | n/a | −$1.26 | |
| Q3 FY25 | −$0.42 | −200% | −$1.43 | |
| Q2 FY25 | −$0.25 | −164% | −$0.59 | |
| Q1 FY25 | −$0.53 | n/a | $0.05 | |
| Q4 FY24 | −$0.23 | n/a | $0.23 | |
| Q3 FY24 | $0.42 | n/a | −$0.84 | |
| Q2 FY24 | $0.39 | n/a | −$2.46 | |
| Q1 FY24 | −$0.35 | n/a | −$3.28 | |
| Q4 FY23 | −$1.30 | n/a | −$3.30 |
Against its peers
Companies in Drug Manufacturers - General nearest Lifecore Biomedical's size, closest first, today.
| Company | EPS, 12 months | Growth |
|---|---|---|
| LFCRLifecore Biomedical | n/m | |
| NATRNatures Sunshine Products | $1.01 | +36% a year |
| ARVNArvinas | $0.16 | |
| PBYIPuma Biotechnology | $0.52 | −47% a year |
| IRWDIronwood Pharmaceuticals | $0.77 | |
| ZVRAZevra Therapeutics | $0.93 | |
| CRMDCorMedix | $2.13 | +184% a year |
| COLLCollegium Pharmaceutical | $1.24 | +19% a year |
| LFVNLifevantage | $0.40 | −46% a year |
| ABUSArbutus Biopharma | $0.78 | |
| SPROSpero Therapeutics | $0.11 | |
| Peer median | $0.78 |
What the EPS figure tells you
Net income divided by diluted shares. The denominator of PE.
One-off charges and gains swing it. The TTM view smooths a single odd quarter.
More on Lifecore Biomedical
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.